Kidswell Bio Corporation (4584) Cash flow
Market cap
¥7B
P/E ratio
KidsWell Bio develops biosimilar drugs and regenerative medicine treatments using SQ-SHED stem cells from baby teeth for pharmaceutical partners and rare disease patients.
| 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 0 |
| Cash from operations | -971 | -607 | -1,759 | -438 | -860 | -1,325 | -1,267 | -1,170 | -1,421 | -454 | 937 | -1,096 |
| Capital expenditures | - | -2 | - | -0 | - | -2 | - | - | - | - | -6 | -18 |
| Cash from investing | -50 | -122 | -150 | -50 | -0 | -137 | -22 | 527 | -29 | - | 65 | -13 |
| Repurchases of common stock | - | - | - | - | - | - | - | - | - | - | - | - |
| Proceeds from issuance of term debt, net | - | - | - | - | - | 582 | - | - | 970 | 1,000 | - | 2,500 |
| Repayments of term debt | - | - | - | - | - | - | - | - | -150 | -375 | -737 | -1,413 |
| Cash from financing | 10 | 947 | 3,472 | - | 978 | 1,222 | 718 | 369 | 1,356 | 1,618 | -240 | 1,398 |